Oncology Account Based Marketing for Specialty Pharma

Oncology account based marketing (ABM) is a way for specialty pharma to focus outreach on specific healthcare organizations and the people who influence care decisions. It can help align marketing, sales, and medical affairs for oncology products with complex evidence and high stakeholder involvement. This article explains how oncology ABM works, what data and targeting usually look like, and how to build a practical program for specialty pharma. It also covers key goals like demand generation, account planning, and message testing.

Specialty pharma teams often need ABM because oncology buyers vary by site of care, treatment pathway, and clinical specialty. Many buying committees, tumor boards, and formulary stakeholders also involve multiple roles. A well-run ABM approach supports consistent outreach across these groups.

For a demand generation partner that focuses on oncology, the oncology demand generation agency services from AtOnce may help connect ABM planning with execution and content workflows. This type of support can be useful when teams need both strategy and campaign operations.

Operational details matter in oncology because timelines, evidence needs, and compliance steps differ by account type. The sections below cover a beginner path first, then deeper planning and measurement.

What oncology account based marketing means for specialty pharma

Core goal: targeted engagement, not broad lead capture

Oncology ABM focuses on accounts such as hospitals, cancer centers, integrated delivery networks, large oncology clinics, and specialty pharmacies. The goal is usually to create relevance for a defined set of accounts and decision makers.

Unlike broad demand generation, oncology ABM often starts with account lists and then maps stakeholders inside those accounts. This can include medical directors, pharmacy and therapeutics committees, site leadership, research coordinators, and patient services teams.

Account types and stakeholder roles in oncology

Specialty pharma often treats oncology as a network of stakeholders rather than a single buyer. Common account stakeholders can include:

• Clinical leadership (oncology department chairs, disease site leads)
• Pharmacy and formulary (pharmacy directors, P&T committee members, formulary managers)
• Practice operations (infusion center managers, pathway coordinators)
• Research and trials (clinical trials office, study coordinators)
• Care management and patient support (support programs, prior authorization teams)

How oncology ABM fits with medical affairs and compliance

Oncology ABM is often a cross-functional effort. Medical affairs may guide evidence-based content, while marketing may manage campaign channels and audience targeting.

Because oncology products can require careful claims handling, ABM programs usually include review steps for promotional materials and educational content. Many teams also set rules for how claims, indications, and safety information appear across channels.

Oncology buyer journey and ABM planning

Buyer journey basics for cancer care decisions

The oncology buyer journey can involve multiple steps, such as learning about a therapy, comparing evidence, planning operational fit, and preparing formulary or pathway alignment. These steps may repeat across disease subtypes and line-of-therapy contexts.

For an oncology-focused view of this process, see oncology buyer journey guidance. It can help connect ABM messaging and timing with how organizations evaluate therapies.

Mapping account needs to oncology phases

ABM planning often uses a simple structure: discovery, evidence review, decision support, and adoption support. Each phase may require different content and different channel priorities.

• Discovery: education on disease, patient selection, and treatment pathway context
• Evidence review: comparative data summaries, safety and administration details, guidelines and positioning
• Decision support: formulary planning inputs, value discussion frameworks, HCP-facing materials for meetings
• Adoption support: operational resources, patient access support, and site workflow materials

Using market positioning to shape ABM account messages

Oncology ABM works better when messaging is consistent across accounts and channels. Positioning should reflect the therapy’s clinical role, differentiation themes, and practical fit for oncology sites.

For background on positioning work that supports account-based outreach, consider oncology market positioning resources. These resources can help teams translate product strategy into clear claims-ready narratives.

Targeting and account selection for specialty pharma oncology

Defining account tiers: strategic, growth, and expansion

Most oncology ABM programs use account tiers. Strategic accounts typically receive the highest effort, while growth and expansion accounts may receive narrower but still coordinated outreach.

A practical starting point is to define tiers based on disease coverage, site of care, and decision influence. For example, some accounts may have strong access to specific tumor boards or clinical programs.

Data inputs used for oncology account selection

Oncology teams often combine multiple data sources. Exact tools vary, but data usually includes:

• Accountographics: organization type, system size, care delivery model
• Oncology activity signals: treatment volume proxies, disease focus, clinical trial presence
• Provider affiliation: HCP specialty, disease site expertise, institutional roles
• Engagement history: prior content consumption, webinar attendance, event participation
• Commercial and operational context: formulary history patterns and access pathways

Because data can be incomplete or outdated, many teams run a light validation step. This may include internal medical review and sales feedback to confirm the likely relevance of accounts.

Building stakeholder maps within each oncology account

After selecting accounts, ABM usually includes stakeholder mapping. Stakeholder maps help coordinate outreach to the people who influence adoption and the people who support operations.

A stakeholder map can include both named individuals and role-based segments. Named individuals may be used for high-priority accounts. Role-based segments may support broader reach within a system.

Balancing personalization with scale

Personalization in oncology ABM may focus on relevance themes rather than full custom creation for every touch. Many teams personalize by:

• Disease site and line-of-therapy fit
• Evidence focus based on what an account is likely to evaluate
• Operational support needs, such as prior authorization readiness
• Channel selection based on how the account engages

This approach can help scale ABM efforts while keeping messages aligned to account context.

Personalized messaging and creative development for oncology ABM

Message pillars for specialty pharma oncology

Oncology ABM messages often use a small set of message pillars. These pillars typically cover clinical differentiation, patient selection and outcomes considerations, safety and administration, and operational fit for adoption.

Creative and content should then align to each pillar and to the buyer journey phase. For instance, early phases may lean more on education and pathway context, while later phases may focus on evidence and implementation support.

Evidence and claims considerations across channels

Because ABM uses multiple channels, oncology teams often create channel-specific versions of evidence content. This may include HCP slide decks, short-form summaries, and meeting prep guides.

Many programs also define what can be said in each format and how safety information is presented. Review workflows and compliance checks are usually planned before launch.

Message testing to improve relevance

Message quality can affect engagement rates and downstream field impact. Many oncology ABM programs include message testing before scaling.

For a practical view of how message testing can be structured for oncology, see oncology message testing. Testing can help teams confirm which value themes are clear to stakeholders and how wording lands across roles.

Content types commonly used in oncology ABM

Specialty pharma teams often combine education content with operational and stakeholder-specific materials. Common content types include:

• Disease and pathway overview one-pagers
• Evidence summaries aligned to clinical decision needs
• Safety and administration explainers for site operations
• Formulary and access support content for pharmacy stakeholders
• Meeting guides for sales and medical discussions
• Patient support program briefs for patient services teams

Content should also be mapped to the account tier. Strategic accounts may receive more tailored sequences, while growth accounts may receive standardized but relevant content.

Channels and orchestration in oncology account based marketing

Field alignment: combining ABM with sales and medical affairs motions

In specialty pharma, ABM often succeeds when marketing and field teams operate together. Field alignment can include shared account plans, shared objectives, and shared timing for key events.

Marketing can run coordinated campaigns, while sales and medical affairs may schedule account visits or meetings. Many teams define when a channel supports the field and when the field supports the channel.

Digital engagement channels used in oncology ABM

Digital channels can support account-based outreach by reinforcing key themes between in-person meetings. Common channels include:

• Account-targeted display and video ads tied to disease site topics
• Triggered email sequences for engagement milestones
• Webinars and virtual roundtables for clinical and operational questions
• Content syndication for high-intent educational assets
• Landing pages that reference disease and account-relevant pathways

Channel choices may vary based on compliance rules and account preferences. Some accounts may engage more through education events, while others may respond more to sales-led workflows.

Events and meetings as a core ABM lever

Oncology ABM often uses meetings and events to create deeper engagement. This can include advisory roundtables, speaker programs, disease site symposia, and institution-level conversations.

To support ABM, event planning usually includes a stakeholder list, meeting objectives, and pre- and post-event content sequences. Post-event follow-up should reflect what was discussed and what the next step is.

Orchestration and sequencing basics

Orchestration means planning a sequence of touches. A simple structure can work well:

1. Introduce the topic aligned to the buyer journey phase
2. Provide evidence and operational context
3. Invite to an education event or meeting
4. Offer decision support content after engagement

Sequencing also helps manage frequency and reduce overlap. Many teams set rules for how often stakeholders within an account receive similar messages.

Account planning process for oncology ABM programs

Account plans: what to include

An oncology account plan usually lays out the account objective, stakeholders, and engagement path. It also ties messaging themes to the buyer journey and sets a timeline.

A typical account plan section list includes:

• Account overview and likely decision context
• Disease area focus and product relevance themes
• Stakeholder map and engagement history
• Buyer journey phase targets for the next quarter
• Channel plan and field support plan
• Content assets to support each phase
• Next steps and owners for each action

Coordinating internal owners and roles

Oncology ABM often requires clear role ownership. Marketing may own campaign orchestration and content delivery. Sales and medical affairs may own meetings, evidence conversations, and account updates.

Many programs add an internal review cadence. This can include a weekly operating meeting for active accounts and a monthly review for pipeline and performance.

Using insights from engagement to refine account plans

Account plans should not stay fixed. As engagement signals arrive, teams can refine messaging and channel choice.

For example, if stakeholders engage more with safety and administration content, future sequences can prioritize those materials. If evidence summaries receive more attention near formulary discussions, that content can be scheduled closer to key account milestones.

Measurement and outcomes for oncology account based marketing

Choosing ABM success metrics that match the motion

Because oncology ABM includes multiple stages, measurement should reflect both engagement and progress. Metrics often fall into three groups: account engagement, stakeholder engagement, and business outcomes.

Common account engagement metrics include:

• Target account coverage (how many target accounts show meaningful engagement)
• Engaged account rate by tier
• Attendance or participation in account-targeted events

Stakeholder engagement metrics may include:

• Content consumption on key evidence assets
• Webinar registrations and viewing completion
• Meeting requests linked to account activities

Business outcome metrics can include:

• Formulary or pathway movement indicators
• Increased field opportunities tied to ABM accounts
• Repeat engagement across multiple stakeholders within the same account

Connecting ABM engagement to field impact

In specialty pharma, ABM can influence how discussions progress, not only whether content is opened. A measurement approach that connects marketing touches to field next steps can be more useful.

Many teams use structured CRM notes and meeting outcomes to record which ABM activities contributed to a specific conversation or decision step. This can improve learning across quarters.

Feedback loops: what to do when signals are weak

Some account targets may not respond as expected. In oncology ABM, this can happen due to timing, competing evidence needs, or leadership changes.

When engagement is weak, teams often revisit:

• Account selection and stakeholder map accuracy
• Whether the message fits the buyer journey phase
• Channel mix and sequencing
• Creative clarity and claims readability

A short learning cycle can help reduce wasted spend and keep ABM aligned with account reality.

Implementation roadmap for oncology ABM in specialty pharma

Step 1: define scope, tiers, and objectives

Start with a clear scope. Define which product(s) and disease areas are in scope, which account tiers will be used, and what the near-term objectives are.

Objectives often include education goals, meeting conversion goals, and evidence review support. These objectives should map to buyer journey phases.

Step 2: build the account list and stakeholder map

Develop the account list using available data inputs. Then confirm stakeholders through internal review and sales or medical feedback.

For each strategic account, create an account plan draft and define who owns the next step actions.

Step 3: align messaging, content, and compliance review

After positioning and message pillars are set, build channel-ready content. Ensure the compliance review workflow is ready before campaigns launch.

Message testing can be scheduled before full rollout, especially for new claims themes or new disease framing.

Step 4: orchestrate campaigns and field activities

Launch digital sequences for account audiences and coordinate meeting invitations where appropriate. Confirm sales and medical affairs timing so ABM touches support field objectives.

For example, a sequence that shares evidence summaries can precede a sales call, while a meeting prep guide can be delivered after an initial conversation.

Step 5: measure, learn, and improve the next quarter plan

Use engagement and account progress metrics to evaluate results. Then update account tiers, refine stakeholder maps, and adjust message and channel sequencing.

Many teams also capture lessons learned about content formats that support evidence review and operational adoption.

Example oncology ABM scenarios for specialty pharma

Example 1: strategic hospital network for a disease site program

A specialty pharma team targets a hospital network with strong disease site expertise. The account plan focuses on evidence review and formulary preparation.

• Marketing runs targeted content for key evidence assets and patient selection education
• Sales supports by scheduling account meetings with clinical leadership and pharmacy stakeholders
• Medical affairs provides disease site education at a site roundtable
• Follow-up includes decision support materials for formulary discussions

Example 2: expansion into research-forward cancer centers

A second ABM motion targets research-active cancer centers. The buyer journey focus shifts toward adoption support and clinical program alignment.

• Webinars focus on evidence and safety and include Q&A with medical experts
• Content includes operational notes for treatment administration workflows
• Events highlight collaboration opportunities such as trial awareness and protocol-fit discussions

Example 3: improving engagement with late-stage pipeline education

For growth accounts with limited early engagement, ABM can focus on clarity. Messaging may be refined based on feedback and message testing results.

• Shorter evidence summaries replace longer decks for early phases
• Landing pages use disease site and line-of-therapy context to reduce confusion
• Sequencing changes to emphasize operational and access support content sooner

Common challenges in oncology ABM and practical fixes

Challenge: unclear stakeholder ownership inside accounts

When stakeholders are not mapped clearly, outreach may miss the decision maker or duplicate messages to the wrong role. A fix is to maintain a stakeholder map that includes role-based segments and named priority contacts.

Challenge: content that does not match the buyer journey phase

If content is too advanced for early discovery, engagement may drop. A practical fix is to align content to discovery, evidence review, decision support, and adoption support with simple content labeling.

Challenge: fragmented execution across marketing, sales, and medical affairs

ABM can fail when teams operate in parallel without shared timing. A fix is to use account plans with owners, next steps, and a shared cadence for review.

Challenge: compliance review bottlenecks

Oncology ABM uses many assets across channels, which can slow launch if reviews are not planned. A fix is to define review SLAs, create reusable compliant templates, and pre-approve core message pillars.

How to choose an oncology ABM partner or agency

What to look for in oncology demand generation and ABM support

Some specialty pharma teams work with agencies or vendors for execution, creative, and measurement. When evaluating partners, it can help to confirm oncology-specific capability across strategy, content operations, and channel orchestration.

One helpful starting point is to review an oncology demand generation agency approach that can connect account-based planning with campaign delivery and learning loops.

Questions to ask before engagement

• How are account tiers defined and validated?
• How are stakeholder maps created and kept up to date?
• What message testing and compliance workflows are included?
• How does orchestration connect with field and medical meetings?
• What reporting ties account engagement to business outcomes?

Conclusion

Oncology account based marketing for specialty pharma is built around focused account lists, mapped stakeholders, and buyer journey-aligned messaging. It often requires strong coordination between marketing, sales, and medical affairs, plus clear compliance workflows. A practical ABM program also includes measurement that tracks account progress, not only digital clicks.

With a phased roadmap and ongoing account plan updates, oncology ABM can help specialty pharma teams create more relevant outreach across complex oncology decision environments.